Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

NCT00150800 is registered in ClinicalTrials.gov with UCB PHARMA Inc. (US) as lead sponsor.

NCT NCT00150800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00150800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy
Lead sponsor
UCB PHARMA Inc. (US)
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
September 30, 2017
Enrollment
668 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy